Author:
Cao Joan,Zhu Zhou,Wang Hui,Nichols Timothy C.,Lui Goldie Y. L.,Deng Shibing,Rejto Paul A.,VanArsdale Todd,Hardwick James S.,Weinrich Scott L.,Wei Ping
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Molecular Biology
Reference53 articles.
1. O’Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol. 2016;13:417–30.
2. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004;3:1427–38.
3. VanArsdale T, Boshoff C, Arndt KT, Abraham RT. Molecular pathways: targeting the Cyclin D-CDK4/6 axis for cancer treatment. Clin Cancer Res. 2015;21:2905–10.
4. Dhillon S. Palbociclib: first global approval. Drugs. 2015;75:543–51.
5. Syed YY. Ribociclib: first global approval. Drugs. 2017;77:799–807.
Cited by
32 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献